Min K. Tsai

Min K. Tsai

Auto-generated profile, based on publicly available information

Min K. Tsai

Department of Genetics, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Cancer Discovery
Verified
Journal Article
Closed access
CMChristopher W. Murray
Christopher W. Murray
JBJennifer J. Brady
Jennifer J. Brady
MTMin K. Tsai
Min K. Tsai
CLChuan Li
Chuan Li
IWIan P. Winters
Ian P. Winters
MWMonte M. Winslow
Monte M. Winslow
The kinase LKB1 is a critical tumor suppressor in sporadic and familial human cancers, yet the mechanisms by which it suppresses tumor growth remain poorly understood. To investigate the tumor-suppressive capacity of four canonical families of LKB1 substrates in vivo, we used CRISPR/Cas9-mediated combinatorial genome editing in a mouse model of oncogenic KRAS-driven lung adenocarcinoma. We demonstrate that members of the SIK family are critical for constraining tumor development. Histologic and gene-expression similarities between LKB1- and SIK-deficient tumors suggest that SIKs and LKB1 operate within the same axis. Furthermore, a gene-expression signature reflecting SIK deficiency is enriched in LKB1-mutant human lung adenocarcinomas and is regulated by LKB1 in human cancer cell lines. Together, these findings reveal a key LKB1–SIK tumor-suppressive axis and underscore the need to redirect efforts to elucidate the mechanisms through which LKB1 mediates tumor suppression. Significance: Uncovering the effectors of frequently altered tumor suppressor genes is critical for understanding the fundamental driving forces of cancer growth. Our identification of the SIK family of kinases as effectors of LKB1-mediated tumor suppression will refocus future mechanistic studies and may lead to new avenues for genotype-specific therapeutic interventions. This article is highlighted in the In This Issue feature, p. 1469

30 March 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MGMichael A. Gonzalez
Michael A. Gonzalez
DLDaniel R. Lu
Daniel R. Lu
MYMaryam Yousefi
Maryam Yousefi
AKAshley Kroll
Ashley Kroll
CLChen Hao Lo
Chen Hao Lo
KTKristin V. Tarbell
Kristin V. Tarbell
Phagocytosis is a key macrophage function, but how phagocytosis shapes tumor-associated macrophage (TAM) phenotypes and heterogeneity in solid tumors remains unclear. Here, we utilized both syngeneic and novel autochthonous lung tumor models in which neoplastic cells express the fluorophore tdTomato (tdTom) to identify TAMs that have phagocytosed neoplastic cells in vivo. Phagocytic tdTompos TAMs upregulated antigen presentation and anti-inflammatory proteins, but downregulated classic proinflammatory effectors compared to tdTomneg TAMs. Single-cell transcriptomic profiling identified TAM subset-specific and common gene expression changes associated with phagocytosis. We uncover a phagocytic signature that is predominated by oxidative phosphorylation (OXPHOS), ribosomal, and metabolic genes, and this signature correlates with worse clinical outcome in human lung cancer. Expression of OXPHOS proteins, mitochondrial content, and functional utilization of OXPHOS were increased in tdTompos TAMs. tdTompos tumor dendritic cells also display similar metabolic changes. Our identification of phagocytic TAMs as a distinct myeloid cell state links phagocytosis of neoplastic cells in vivo with OXPHOS and tumor-promoting phenotypes.

2 August 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
SPSarah E. Pierce
Sarah E. Pierce
JGJeffrey M. Granja
Jeffrey M. Granja
MCM. Ryan Corces
M. Ryan Corces
JBJennifer J. Brady
Jennifer J. Brady
MTMin K. Tsai
Min K. Tsai
MWMonte M. Winslow
Monte M. Winslow

19 February 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
HCHongchen Cai
Hongchen Cai
SCSu Kit Chew
Su Kit Chew
CLChuan Li
Chuan Li
MTMin K. Tsai
Min K. Tsai
LALaura Andrejka
Laura Andrejka
MWMonte M. Winslow
Monte M. Winslow
Cancer genotyping has identified a large number of putative tumor suppressor genes. Carcinogenesis is a multistep process, but the importance and specific roles of many of these genes during tumor initiation, growth, and progression remain unknown. Here we use a multiplexed mouse model of oncogenic KRAS–driven lung cancer to quantify the impact of 48 known and putative tumor suppressor genes on diverse aspects of carcinogenesis at an unprecedented scale and resolution. We uncover many previously understudied functional tumor suppressors that constrain cancer in vivo. Inactivation of some genes substantially increased growth, whereas the inactivation of others increases tumor initiation and/or the emergence of exceptionally large tumors. These functional in vivo analyses revealed an unexpectedly complex landscape of tumor suppression that has implications for understanding cancer evolution, interpreting clinical cancer genome sequencing data, and directing approaches to limit tumor initiation and progression.Significance: Our high-throughput and high-resolution analysis of tumor suppression uncovered novel genetic determinants of oncogenic KRAS–driven lung cancer initiation, overall growth, and exceptional growth. This taxonomy is consistent with changing constraints during the life history of cancer and highlights the value of quantitative in vivo genetic analyses in autochthonous cancer models.This article is highlighted in the In This Issue feature, p. 1601

12 January 2023 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
RTRui Tang
Rui Tang
ESEmily G. Shuldiner
Emily G. Shuldiner
MKMarcus Kelly
Marcus Kelly
CMChristopher W. Murray
Christopher W. Murray
JHJess D. Hebert
Jess D. Hebert
MWMonte M. Winslow
Monte M. Winslow

28 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CMChristopher W. Murray
Christopher W. Murray
JBJennifer J. Brady
Jennifer J. Brady
MHMingqi Han
Mingqi Han
HCHongchen Cai
Hongchen Cai
MTMin K. Tsai
Min K. Tsai
MWMonte M. Winslow
Monte M. Winslow
LKB1is among the most frequently altered tumor suppressors in lung adenocarcinoma. Inactivation ofLkb1accelerates the growth and progression of oncogenic KRAS-driven lung tumors in mouse models. However, the molecular mechanisms by which LKB1 constrains lung tumorigenesis and whether the cancer state that stems fromLkb1deficiency can be reverted remains unknown. To identify the processes governed by LKB1 in vivo, we generated an allele which enablesLkb1inactivation at tumor initiation and subsequentLkb1restoration in established tumors. Restoration ofLkb1in oncogenic KRAS-driven lung tumors suppressed proliferation and led to tumor stasis.Lkb1restoration activated targets of C/EBP transcription factors and drove neoplastic cells from a progenitor-like state to a less proliferative alveolar type II cell-like state. We show that C/EBP transcription factors govern a subset of genes that are induced by LKB1 and depend upon NKX2-1. We also demonstrate that a defining factor of the alveolar type II lineage, C/EBPα, constrains oncogenic KRAS-driven lung tumor growth in vivo. Thus, this key tumor suppressor regulates lineage-specific transcription factors, thereby constraining lung tumor development through enforced differentiation.